Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.37 |
| ▸ | PPARA | Q07869 | 15/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899076 | 0.91 | PPARA (0.43) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL13904973 | 0.89 | PPARA (0.37) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL13899072 | 0.86 | PPARA (0.45) | PPARDPPARAPPARG | |
| SCHEMBL13899343 | 0.82 | PPARA (0.41) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL13899325 | 0.81 | PPARA (0.52) | PPARDPPARAPPARG | |
| SCHEMBL13904970 | 0.80 | PPARA (0.42) | PPARDPPARATP53MAPTPPARG | |
| SCHEMBL13899317 | 0.76 | PPARA (0.55) | PPARDPPARAPPARG | |
| SCHEMBL13904969 | 0.76 | PPARA (0.43) | PPARDPPARAPPARG | |
| SCHEMBL13899100 | 0.73 | PPARD (0.43) | PPARDPPARAMAPTPPARG | |
| SCHEMBL13899329 | 0.73 | PPARA (0.45) | PPARDPPARAPPARGNR3C1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112045-A1 | Triazole ppar modulators | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885TP53 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.